The study is aimed at observing the influence of microribonucleic acid- (miRNA-) 30a-50p on the pulmonary fibrosis in mice with Streptococcus pneumoniae infection through the regulation of autophagy by Beclin-1. Specific pathogen-free mice were instilled with Streptococcus pneumoniae through the trachea to establish the pulmonary fibrosis model. Then, they were divided into the miRNA-30a-50p mimics group (mimics group, n = 10) and miRNA-30a-5p inhibitors group (inhibitors group, n = 10), with the control group (n = 10) also set. Pulmonary tissue wet weight/dry weight (W/D) was detected. The content of tumor necrosis factor-α (TNF-α), interleukin- (IL-) 6, and myeloperoxidase (MPO) was determined using enzyme-linked immunosorbent assay (ELISA). Besides, the changes in the pulmonary function index dynamic lung compliance (Cdyn), plateau pressure (Pplat), and peak airway pressure (Ppeak) were monitored, and the gene and protein expression levels were measured via quantitative PCR (qPCR) and Western blotting. The expression level of miRNA-30a-5p was substantially raised in the mimics group (p < 0.05), but extremely low in the inhibitors group (p < 0.05). The mimics group had obviously raised levels of serum aminotransferase (AST), glutamic-pyruvic transaminase (GPT), alkaline phosphatase (ALP), and pulmonary tissue W/D (p < 0.05). Additionally, the expression levels of TNF-α, IL-6, and MPO were notably elevated in the mimics group, while their expression levels showed the opposite conditions in the inhibitors group (p < 0.05). According to the HE staining results, the inhibitors group had arranged orderly cells, while the mimics group exhibited lung injury, pulmonary edema, severe inflammatory response, and alveolar congestion. In the inhibitors group, Cdyn was remarkably elevated, but Pplat and Ppeak declined considerably (p < 0.05). Besides, the inhibitors group exhibited elevated messenger RNA (mRNA) levels of Beclin-1 and LC3, lowered mRNA levels of α-SMA and p62, a raised protein level of Beclin-1, and a markedly decreased protein level of p62 (p < 0.05). Silencing miRNA-30a-5p expression can promote the expression of Beclin-1 to accelerate the occurrence of autophagy, thereby treating pulmonary fibrosis in mice with Streptococcus pneumoniae infection.
The study is aimed at observing the influence of microribonucleic acid- (miRNA-) 30a-50p on the pulmonary fibrosis in mice with Streptococcus pneumoniae infection through the regulation of autophagy by Beclin-1. Specific pathogen-free mice were instilled with Streptococcus pneumoniae through the trachea to establish the pulmonary fibrosis model. Then, they were divided into the miRNA-30a-50p mimics group (mimics group, n = 10) and miRNA-30a-5p inhibitors group (inhibitors group, n = 10), with the control group (n = 10) also set. Pulmonary tissue wet weight/dry weight (W/D) was detected. The content of tumor necrosis factor-α (TNF-α), interleukin- (IL-) 6, and myeloperoxidase (MPO) was determined using enzyme-linked immunosorbent assay (ELISA). Besides, the changes in the pulmonary function index dynamic lung compliance (Cdyn), plateau pressure (Pplat), and peak airway pressure (Ppeak) were monitored, and the gene and protein expression levels were measured via quantitative PCR (qPCR) and Western blotting. The expression level of miRNA-30a-5p was substantially raised in the mimics group (p < 0.05), but extremely low in the inhibitors group (p < 0.05). The mimics group had obviously raised levels of serum aminotransferase (AST), glutamic-pyruvic transaminase (GPT), alkaline phosphatase (ALP), and pulmonary tissue W/D (p < 0.05). Additionally, the expression levels of TNF-α, IL-6, and MPO were notably elevated in the mimics group, while their expression levels showed the opposite conditions in the inhibitors group (p < 0.05). According to the HE staining results, the inhibitors group had arranged orderly cells, while the mimics group exhibited lung injury, pulmonary edema, severe inflammatory response, and alveolar congestion. In the inhibitors group, Cdyn was remarkably elevated, but Pplat and Ppeak declined considerably (p < 0.05). Besides, the inhibitors group exhibited elevated messenger RNA (mRNA) levels of Beclin-1 and LC3, lowered mRNA levels of α-SMA and p62, a raised protein level of Beclin-1, and a markedly decreased protein level of p62 (p < 0.05). Silencing miRNA-30a-5p expression can promote the expression of Beclin-1 to accelerate the occurrence of autophagy, thereby treating pulmonary fibrosis in mice with Streptococcus pneumoniae infection.
Idiopathic pulmonary fibrosis (IPF), a series of heterogeneous diffuse nonneoplastic diseases, initially occurs with the feature of alveolar epithelial cell injury and then is accompanied by excessive migration, activation, and proliferation of fibroblasts in extracellular matrix remodeling [1, 2]. IPF is characterized by inflammation and fibrosis, the most representative of which is idiopathic pulmonary failure, a progressive disease with the mean survival of 3 years. Despite in-depth research, the exact potential pathogenesis of IPF remains unclear [3]. IPF is generally considered to be a persistent damage-induced disease that is most likely to cause inflammation, and then, the expansion and proliferation of fibroblasts and deposition of extracellular matrix as well as irreversible obstructive pulmonary function decline, ultimately resulting in irreversible restrictive lung function deterioration and death [4]. It is a major breakthrough on this disease that macrolide treatment has been found to be able to prevent the progression of disease and even improve pulmonary function [5], which is, however, only applicable to the patients with increased neutrophilic granulocytes in the airway. Some experiments have also manifested that neutrophilic granulocyte-induced inflammation may play a role in the pathogenesis of IPF [6]. Although previous research focuses on parenchyma, the peripheral airway and vessels are probably involved in the pathogenesis of pulmonary fibrosis [7]. According to a study, blocking inflammation can prevent neutrophilic granulocytes from flowing into the airway, repressing pulmonary fibrosis [8].Autophagy, a programmed death method, is strictly modulated by autophagy genes and can timely scavenge the wastes produced by cells in maintaining their own life activities, which serves as a metabolic pathway [9]. Besides, autophagy can clear harmful substances in cells, and once cells are invaded, it will make the corresponding response to keep the cells stable as a defender in organisms. Now, the research of autophagy has become a hotspot in the field of biology [10]. The mechanism of action of autophagy in physiological metabolisms in organisms has not yet been fully clarified currently, but the elucidated mechanism of action and pathway can be taken as crucial guidelines for the clinical cases of such diseases as tumor and pulmonary fibrosis. At present, the therapeutic means for pulmonary fibrosis is dominated by the antagonistic treatment for early inflammatory factors, but the efficacy is less favorable. Therefore, it is a top priority to search for ideal novel treatment strategies. The achievements in the genetic research in recent years have provided new strategies for the treatment of pulmonary fibrosis. More and more studies have demonstrated that most of human genes may be regulated by microribonucleic acids (miRNAs) [11]. miRNAs, noncoding RNAs, are involved in the specific regulation of protein coding and noncoding genes as well as multiple processes, such as cell cycle, metabolism and various immune responses [12]. A study revealed that the roles of miRNAs in the pathogenesis of different diseases are fully explored and that they play important roles in physiology and various diseases and has become crucial regulators for gene expression in many diseases, with their regulatory networks receiving extensive attention in recent years [13]. Nevertheless, the specific mechanism of the influence of miRNA-30a-50p on the pulmonary fibrosis in mice with Streptococcus pneumoniae infection through the regulation of autophagy by Beclin-1 remains less clear and needs to be delved into by researchers further.The present study is aimed at exploring the influence of miRNA-30a-50p on the pulmonary fibrosis in mice with Streptococcus pneumoniae infection through the regulation of autophagy by Beclin-1 using the classical pulmonary fibrosis animal model established in mice with Streptococcus pneumoniae infection, biochemical index detection, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting for determining the changes in autophagy genes and proteins. It reveals the therapeutical effect of miRNA-30a-5p on the pulmonary fibrosis in mice with Streptococcus pneumoniae infection through the regulation of autophagy by Beclin-1, providing experimental bases and theoretical references for the subsequent research and development of novel drugs.
2. Materials and Methods
2.1. Common Reagents and Consumables
Specific pathogen-free (SPF) mice (Shanghai Institutes for Biological Sciences, CSA), TRIzol reagent, DEPC-treated water, SuperScript III reverse transcriptase kit and SYBR quantitative polymerase chain reaction (qPCR) mix (ABI), radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Biotechnology), loading buffer, protease inhibitor and bicinchoninic acid (BCA) protein concentration assay kit (Biosharp), tumor necrosis factor-α (TNF-α), interleukin- (IL-) 6 and myeloperoxidase (MPO) enzyme-linked immunosorbent assay (ELISA) kit (Nanjing Jiancheng Bioengineering Institute), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and secondary antibodies (Boster Biological Technology Co., Ltd.), primary antibodies (Santa Cruz Biotechnology, Inc.), microplate reader (Thermo Fisher Scientific), 7900HT Fast qPCR instrument (Applied Biosystems) and 2500 gel imaging system, tissue homogenizer, and electrophoresis apparatus (Bio-Rad, USA) are used.
2.2. Establishment of Animal Model and Grouping
Twenty SPF mice were selected. The mice were fed and drank freely at a temperature of 24 ± 2°C, a humidity of 56 ± 14%, and 12 hours a day and night and were reared adaptively for 1 week. Then, a pulmonary fibrosis model was established by instilling Streptococcus pneumoniae through the trachea. Streptococcus pneumoniae bacterial solution was 0.15 mL/piece (China Institute for the Control of Pharmaceutical and Biological Products, No. 31003, 2 generations of resuscitation, colony number 3 × 1011/L). Two weeks after modeling, the nontissues of mice showed pulmonary fibrosis and alveolitis, and the content of hydroxyproline was significantly increased. And the expression level of α-smooth muscle actin and collagen in the lung tissue is obviously increased, which is regarded as a successful modeling.In adenovirus transfection, construction of miRNA-30a-5p overexpression or silencing adenovirus vector, the related gene sequence is designed and synthesized by Shanghai Jikai Gene Company. The adenovirus mother liquor is dissolved by centrifugation and diluted with a sterile phosphate buffer into an adenovirus suspension with a titer of 5 × 105 TU/μL, liposome 2000 was used to transfer the expression of miRNA-30a-5p to an adenovirus vector, and the relevant adenovirus was instilled into the trachea for transfection into mice, specifically divided into the miRNA-30a-5p inhibitors group (inhibitors), miRNA-30a-5p mimics group (mimics). Another normal control group was set up, and the control group was intratracheally injected with an equal volume of normal saline under the same conditions, 10 rats in each group. The experimental protocol was approved by the experimental animal ethics committee of our hospital, and each group continued to be fed for 2 weeks, and after the end of the test period, blood and lung tissue samples were collected from mice in each group. Lung tissues were preserved in 4% paraformaldehyde for HE staining in one part and the expression of genes and proteins to be tested in a -80 freezer.
2.3. Evaluation of Transfection Efficiency of miRNA-30a-5p in each Group of Pulmonary Tissues
miRNA-30a-5p was transfected into mice using adenoviruses, and then, the transfection efficiency of miRNA-30a-5p in the pulmonary tissues was determined via reverse transcription- (RT-) PCR. After anesthesia via intraperitoneal injection of pentobarbital sodium, appropriate numbers of pulmonary tissues were taken carefully and smashed using the tissue homogenizer, and the expression level of miRNA-30a-5p was measured to prepare for the subsequent research of the specific molecular mechanism of action of miRNA-30a-5p in pulmonary fibrosis.
2.4. Detection of Aspartate Aminotransferase (AST), Glutamic-Pyruvic Transaminase (GPT), Alkaline Phosphatase (ALP), and Wet Weight/Dry Weight (W/D)
At the end of trial, eyeball blood was collected routinely from mice, let stand at room temperature for 30 min, and centrifuged at 3,500× g for 10 min, and the supernatant was harvested for detection of AST, ALP, and GPT. Whether these three indexes changed was observed to further indicate the progression of pulmonary fibrosis. Subsequently, the mice were anesthetized through injection of pentobarbital sodium, and an appropriate number of pulmonary tissues were taken. The surface was dried using a piece of dry sterile ultrathin white filter paper, with such smudges as water and blood removed. After the wet pulmonary tissues were weighed using an analytical electronic balance and the experimental data were recorded in each group, the tissues were carefully placed in the drying oven at 65°C and baked until the weight stayed constant, and the dry weight was measured. The weight value in each group was recorded, and the mean was obtained to calculate the pulmonary tissue W/D.
2.5. Detection of Inflammatory Factors in Pulmonary Tissues
After the mice were anesthetized and sacrificed, pulmonary tissues were harvested and washed using normal saline. A total of 300 mg of pulmonary tissues were taken, broken into pieces using the homogenizer containing the tissue lysis buffer prepared, and centrifuged at 2500× g for 15 min, and the supernatant was obtained to determine the changes in the levels of MPO, IL-6, and TNF-α. Finally, the absorbance of these indexes in each group was measured using the microplate reader, and the standard curves were plotted to analyze the content changes according to the instructions.
2.6. Determination of Pulmonary Function Indexes
The pulmonary function indexes were determined in each group of mice as follows: Dynamic lung compliance (Cdyn), plateau pressure (Pplat), and peak airway pressure (Ppeak) were monitored via side-stream spirometry, and the measurement was repeated for several times to calculate the mean according to the instructions of the instrument. Finally, the data obtained were analyzed in accordance with the manufacturer's specifications.
2.7. HE Staining
The mice to be detected were killed by dislocation, and then, pulmonary tissues were aseptically separated and fixed in 4% paraformaldehyde at 4°C for 48 h. After being washed using running water, the tissues were dehydrated using alcohol at different concentrations, embedded in paraffin, and routinely sliced into 4-5 μm thick sections. Subsequently, the sections were deparaffinized; hydrated in 95%, 90%, 80%, 75%, and 50% ethano; baked dry; and stained with hematoxylin for 20 min. After separation using hydrochloric acid and ethanol solution for 30 s, the resulting tissues were stained with eosin for 12 min, separated with 90% ethanol, and sealed. Finally, the tissues were observed under a light microscope.
2.8. Real-Time qPCR
Total RNAs were extracted from the pulmonary tissues of mice in each group using TRIzol reagent (Invitrogen), and when the purity and concentration of the RNAs were eligible, complementary deoxyribonucleic acid strands were obtained through RT (attention should be paid to the use of isopropanol). Then, the primers were amplified in the amplification system (20 μL) containing 2 μL of cDNAs, 10 μL of mix, 2 μL of primers, and 6 μL of ddH2O for 40 cycles. Subsequently, PCR amplification was performed under the following conditions: predenaturation at 95°C for 2 min and PCR at 94°C for 20 s, 60°C for 20 s, and 72°C for 30 s for 40 cycles. The primer sequences of the target genes and the internal reference GAPDH were designed based on the sequences from the GenBank (Table 1), and the expression levels of the target genes were measured via qRT-PCR. The expression level of mRNAs in the pulmonary tissues of mice in each group was calculated using 2-.
A total of 150 mg of mouse pulmonary tissues were sheared into pieces, weighed, added with RIPA lysis buffer at 100 mg/mL, and homogenized. The concentration of the total proteins extracted in the pulmonary tissues in each group of mice was determined using the BCA assay kit. Subsequently, the proteins were sampled, followed by preparation of gels, and the protein samples were loaded for electrophoresis, transferred onto a membrane, and sealed and incubated with the primary antibodies in the cassette overnight. After incubation with the secondary antibodies for 1 h, the resulting proteins were added with ELC mixture freshly prepared for color development in a darkroom. Afterwards, the protein bands were processed using software, namely, they were scanned and quantified using Odyssey scanner, and protein levels were corrected using GAPDH. Finally, Western blotting bands were quantified using Image-Pro Plus 6.0, and the expression level of each protein was calculated.
2.10. Statistical Analysis
The raw experimental data recorded were processed by SPSS 20.0 analysis software and subjected to multiple comparisons. The experimental results obtained were expressed as mean ± standard deviation (), and p < 0.05 indicated statistically significant differences. GraphPad Prism 5.0 was employed to plot histograms.
3. Experimental Results
3.1. Transfection of miRNA-30a-5p in Each Group of Mice
To observe the transfection efficiency of miRNA-30a-5p in each group of mice, the gene expression level of miRNA-30a-5p was measured in this study. According to the results (Figure 1), the expression level of miRNA-30a-5p was notably raised in the mimics group (p < 0.05), while it was obviously lowered in the inhibitors group (p < 0.05), suggesting that the transfection effect is obvious and can be verified by subsequent experiments.
Figure 1
Transfection efficiency of miRNA-30a-5p. The expression level of miRNA-30a-5p is remarkably raised in the mimics group (p < 0.05), while it evidently declines in the inhibitors group (p < 0.05). ∗p < 0.05 vs. the control group, #p < 0.05 vs. the mimics group.
3.2. Serum AST, GPT, and ALP and Pulmonary Tissue W/D
Important biochemical indicators in serum AST, GPT, ALP, etc. play an important role in pulmonary fibrosis, so we use a conventional biochemical analyzer to detect their content. The results are shown in Table 2. Compared with the control group, the content of AST, GPT, ALP, and lung tissue W/D in the mimics group increased significantly (p < 0.05). Compared with the mimics group, the inhibitors group AST, GPT, ALP, and lung tissue W/D content significantly decreased (p < 0.05).
Table 2
Changes in AST, GPT, ALP, and W/D.
Group
AST (U/L)
W/D
ALP (U/L)
GPT (U/L)
Control
153.2 ± 6.3
3.6 ± 0.2
89.8 ± 5.2
42.3 ± 5.6
Mimics
296.8 ± 2.8∗
10.2 ± 1.3∗
205.5 ± 4.4∗
127.1 ± 5.7∗
Inhibitors
183.6 ± 3.5#
5.3 ± 1.9#
101.1 ± 5.8#
50.7 ± 4.5#
Note: the content of AST, GPT, and ALP and pulmonary tissue W/D decline markedly in the inhibitors group, while they are notably elevated in the mimics group (p < 0.05). ∗p < 0.05 vs. the control group, #p < 0.05 vs. the mimics group.
3.3. Inflammatory Factors in Each Group
In this study, the levels of inflammatory factors such as TNF-α, IL-6, and MPO were detected as shown in Table 3. Compared with the control group, the levels of the three in the mimics group were significantly increased (p < 0.05), and compared with the mimics group, the levels of the three in the inhibitors group were significantly lower (p < 0.05). It shows that lung tissue inflammatory factors are produced in large quantities in pulmonary fibrosis mice, and miRNA-30a-5p inhibitors can inhibit the production of lung tissue inflammatory factors.
Table 3
Levels of inflammatory factors.
Group
TNF-α (fmol/mL)
IL-6 (mg/L)
MPO (U/mg)
Control
33.7 ± 3.1
65.1 ± 4.1
3.5 ± 1.0
Mimics
95.9 ± 6.7∗
134.7 ± 5.2∗
14.6 ± 1.1∗
Inhibitors
42.0 ± 5.8#
75.1 ± 4.0#
4.6 ± 1.8#
Note: the levels of IL-6, TNF-α, and MPO are evidently elevated in the mimics group, but their levels are obviously lowered in the inhibitors group. ∗p < 0.05 vs. the control group, #p < 0.05 vs. the mimics group.
3.4. Pulmonary Function Indexes
As shown in Table 4, compared with the control group, Cdyn in the mimics group was significantly reduced, and Pplat and Ppeak were significantly increased (p < 0.05). Compared with the mimics group, Cdyn in the inhibitors group was significantly increased, while Pplat and Ppeak were significantly decreased (p < 0.05).
Table 4
Pulmonary function indexes.
Group
Cdyn (mL/cmH2O)
Ppeak (cmH2O)
Pplat (cmH2O)
Control
50.7 ± 2.0
9.1 ± 1.1
8.8 ± 2.5
Mimics
24.1 ± 2.3∗
32.1 ± 2.2∗
35.1 ± 2.0∗
Inhibitors
46.1 ± 2.7#
12.5 ± 1.0#
15.4 ± 2.2#
Note: Cdyn is considerably elevated, but Pplat and Ppeak are notably lowered in the inhibitors group (p < 0.05), while they show the opposite trends in the mimics group (p < 0.05). ∗p < 0.05 vs. the control group, #p < 0.05 vs. the mimics group.
3.5. Changes in Pulmonary Tissues Observed via He Staining
The mice in the mimics group had lung injury, pulmonary edema, severe inflammatory response, alveolar congestion, and cell injury (Figure 2(a)), while those in the inhibitors group had cells with basically normal morphology and relatively normal histological structure, without obvious pathological changes compared with the control group (Figure 2(b)).
Figure 2
HE staining results. The mice in the mimics group have lung injury, pulmonary edema, severe inflammatory response, alveolar congestion, and cell injury ((a) ×100), while those in the inhibitors group have cells with basically normal morphology and relatively normal histological structure, without obvious pathological changes compared with the control group ((b) ×100).
3.6. Gene Expression Levels of α-SMA, Beclin-1, LC3, and p62 Determined via RT-PCR
Using RT-PCR technology to detect changes in gene expression levels, the results are shown in Figure 3. Compared with the control group, the expression levels of LC3 and Beclin-1 genes in the mimics group were significantly reduced, and the expression levels of p62 and α-SMA genes were significantly increased (p < 0.05). Compared with the mimics group, the expression levels of LC3 and Beclin-1 genes in the inhibitors group were significantly increased (p < 0.05), and the expression levels of p62 and α-SMA genes were significantly decreased (p < 0.05).
Figure 3
Gene expression levels. The inhibitors group has remarkably raised gene expression levels of LC3 and Beclin-1 (p < 0.05) and markedly decreased gene expression levels of α-SMA and p62 (p < 0.05), while the gene expression trends are the opposite in the mimics group. ∗p < 0.05 vs. the control group, #p < 0.05 vs. the mimics group.
3.7. Expressions of Autophagy-Associated Proteins
We detected the expression levels of two important autophagy proteins, and the results are shown in Figure 4. Compared with the control group, the LC3 and Beclin-1 proteins in the Mimics group were significantly reduced (p <0.05). Compared with the mimics group, LC3 and Beclin-1 proteins in the inhibitors group increased significantly (p < 0.05).
Figure 4
Expressions of autophagy-associated proteins. (a) Western blot result. (b) Quantification analysis of Western blot result. The expression levels of LC3 and Beclin-1 proteins are evidently raised in the inhibitors group (p < 0.05), but they show the opposite conditions in the mimics group. ∗p < 0.05 vs. the control group, #p < 0.05 vs. the mimics group.
4. Discussion
Pulmonary fibrosis is a disease in the lung, which has high morbidity and mortality rates in many children and adults and the features of filling of inflammatory cells, recruitment of fibroblasts, and fibrosis can be secondary to acute lung injury such as acute respiratory distress syndrome and chronic inflammation like cystic fibrosis [14, 15]. The pathological features of pulmonary fibrosis, a fatal disease, may depend on the potential disease process, but its etiology is unclear, so that little has been known about the molecular pathway and cellular mechanism, and there are no efficacious medications or medications have significant side effects [16]. Therefore, there is an urgent need of an efficacious treatment strategy. This study explored the influence of miRNA-30a-5p on the pulmonary fibrosis in mice with Streptococcus pneumoniae infection through the regulation of autophagy by Beclin-1. miRNA-30a-5p was first transfected into mice using adenoviruses, and then the gene expression level of miRNA-30a-5p was measured to observe the transfection efficiency of miRNA-30a-5p in each group of mice. It was found that the expression level of miRNA-30a-5p was notably raised in the mimics group, while it was obviously lowered in the inhibitors group, suggesting that the transfection effect is obvious and can be verified by subsequent experiments. Since sera AST, GPT, and ALP are important indexes in pulmonary fibrosis, their content was determined using a routine biochemical analyzer in this study. According to the detection results, the inhibitors group had substantially lowered content of AST, GPT, and ALP and pulmonary tissue W/D, while they were notably elevated in the mimics group. Additionally, the levels of IL-6, TNF-α, and other inflammatory activation factors are associated with the development of pulmonary fibrosis. Research showed that the increase in B lymphocytes in the lung probably produces such inflammatory factors as IL-6, thus inducing pulmonary fibrosis [17]. In the present research, the levels of the inflammatory factors TNF-α, IL-6, and MPO were determined, and it was found that the levels of these three factors in the mimics group were obviously higher than those in the other two groups, while their levels declined distinctly in the inhibitors group, illustrating that there are massive inflammatory factors in the pulmonary tissues of pulmonary fibrosis mice and that miRNA-30a-5p inhibitors can repress the production of inflammatory factors in pulmonary factors. According to the HE staining results, the mice in the mimics group had lung injury, pulmonary edema, severe inflammatory response, alveolar congestion, and cell injury, while those in the inhibitors group had cells with basically normal morphology and relatively normal histological structure, without obvious pathological changes compared with the control group. Moreover, Cdyn was considerably elevated, but Pplat and Ppeak were notably lowered in the inhibitors group, while they showed the opposite trends in the mimics group, which are consistent with the results of the previous studies. [18]As an evolutionarily conservative mechanism, autophagy maintains the stability of cells through eliminating misfolded/mutated or aggregated proteins and damaged organelles and it allows cells to survive under stress conditions, such as nutrition deficiency, energy deficiency, viral infection, and hypoxia [19]. There is growing evidence that autophagy is likely to help resist cancers, aging, neurodegenerative diseases, and infection [20]. miRNAs have been increasingly proven to be able to regulate cell proliferation, apoptosis, and other basic biological processes and play a pivotal role in the regulation of cell autophagy [21]. Autophagy is modulated by autophagy-associated genes and proteins, including Beclin-1, LC3, and p62, that are involved in autophagosome formation. Research proposed that positively regulating the expression of Beclin-1 gene can accelerate the occurrence of autophagy [22]. LC3, synthesized by ubiquitin-like proteins in cells, is catalyzed by Atg4 homologues to expose some amino acid residues and dissolve in the whole cell cytoplasm [23]. According to the findings in a study, a great increase in the content of p62 gene is detected in the autophagy-defective test, further revealing that the content of p62 is negatively correlated with autophagy intensity [24]. In this study, the influence of miRNA-30a-5p on the pulmonary fibrosis in mice through the regulation of autophagy by Beclin-1 was observed, and according to the gene detection results, the inhibitors group had substantially raised gene expression levels of LC3 and Beclin-1, but notably lowered gene expression levels of p62 and α-SMA, while the mimics group exhibited the opposite conditions. The expression levels of LC3 and Beclin-1, two important autophagy-associated proteins, were also measured in this study, and it was found that the inhibitors group had obviously elevated levels of LC3 and Beclin-1 proteins, but their levels were evidently raised in the mimics group, which is in accordance with the results of the previous studies [25]. The present study proved through a train of animal experiments that silencing miRNA-30a-5p can regulate Beclin-1 to spur the occurrence of autophagy and inhibit the production of inflammatory factors, playing a therapeutical role in pulmonary fibrosis mice.In conclusion, silencing miRNA-30a-5p may protect against pulmonary fibrosis, alleviate inflammatory cell infiltration, enhance pulmonary and biochemical functions and prevent the further progression of inflammation, and ultimately affect the progression of pulmonary fibrosis through activating Beclin-1 to regulate autophagy, so the present research provides a novel theoretical basis of prevention and treatment of pulmonary fibrosis.
Authors: M P Keane; J A Belperio; T A Moore; B B Moore; D A Arenberg; R E Smith; M D Burdick; S L Kunkel; R M Strieter Journal: J Immunol Date: 1999-05-01 Impact factor: 5.422
Authors: Daniel J Klionsky; Fabio C Abdalla; Hagai Abeliovich; Robert T Abraham; Abraham Acevedo-Arozena; Khosrow Adeli; Lotta Agholme; Maria Agnello; Patrizia Agostinis; Julio A Aguirre-Ghiso; Hyung Jun Ahn; Ouardia Ait-Mohamed; Slimane Ait-Si-Ali; Takahiko Akematsu; Shizuo Akira; Hesham M Al-Younes; Munir A Al-Zeer; Matthew L Albert; Roger L Albin; Javier Alegre-Abarrategui; Maria Francesca Aleo; Mehrdad Alirezaei; Alexandru Almasan; Maylin Almonte-Becerril; Atsuo Amano; Ravi Amaravadi; Shoba Amarnath; Amal O Amer; Nathalie Andrieu-Abadie; Vellareddy Anantharam; David K Ann; Shailendra Anoopkumar-Dukie; Hiroshi Aoki; Nadezda Apostolova; Giuseppe Arancia; John P Aris; Katsuhiko Asanuma; Nana Y O Asare; Hisashi Ashida; Valerie Askanas; David S Askew; Patrick Auberger; Misuzu Baba; Steven K Backues; Eric H Baehrecke; Ben A Bahr; Xue-Yuan Bai; Yannick Bailly; Robert Baiocchi; Giulia Baldini; Walter Balduini; Andrea Ballabio; Bruce A Bamber; Edward T W Bampton; Gábor Bánhegyi; Clinton R Bartholomew; Diane C Bassham; Robert C Bast; Henri Batoko; Boon-Huat Bay; Isabelle Beau; Daniel M Béchet; Thomas J Begley; Christian Behl; Christian Behrends; Soumeya Bekri; Bryan Bellaire; Linda J Bendall; Luca Benetti; Laura Berliocchi; Henri Bernardi; Francesca Bernassola; Sébastien Besteiro; Ingrid Bhatia-Kissova; Xiaoning Bi; Martine Biard-Piechaczyk; Janice S Blum; Lawrence H Boise; Paolo Bonaldo; David L Boone; Beat C Bornhauser; Karina R Bortoluci; Ioannis Bossis; Frédéric Bost; Jean-Pierre Bourquin; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan R Brady; Claudio Brancolini; Andreas Brech; Jay E Brenman; Ana Brennand; Emery H Bresnick; Patrick Brest; Dave Bridges; Molly L Bristol; Paul S Brookes; Eric J Brown; John H Brumell; Nicola Brunetti-Pierri; Ulf T Brunk; Dennis E Bulman; Scott J Bultman; Geert Bultynck; Lena F Burbulla; Wilfried Bursch; Jonathan P Butchar; Wanda Buzgariu; Sergio P Bydlowski; Ken Cadwell; Monika Cahová; Dongsheng Cai; Jiyang Cai; Qian Cai; Bruno Calabretta; Javier Calvo-Garrido; Nadine Camougrand; Michelangelo Campanella; Jenny Campos-Salinas; Eleonora Candi; Lizhi Cao; Allan B Caplan; Simon R Carding; Sandra M Cardoso; Jennifer S Carew; Cathleen R Carlin; Virginie Carmignac; Leticia A M Carneiro; Serena Carra; Rosario A Caruso; Giorgio Casari; Caty Casas; Roberta Castino; Eduardo Cebollero; Francesco Cecconi; Jean Celli; Hassan Chaachouay; Han-Jung Chae; Chee-Yin Chai; David C Chan; Edmond Y Chan; Raymond Chuen-Chung Chang; Chi-Ming Che; Ching-Chow Chen; Guang-Chao Chen; Guo-Qiang Chen; Min Chen; Quan Chen; Steve S-L Chen; WenLi Chen; Xi Chen; Xiangmei Chen; Xiequn Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Zhixiang Chen; Alan Cheng; Christopher H K Cheng; Yan Cheng; Heesun Cheong; Jae-Ho Cheong; Sara Cherry; Russ Chess-Williams; Zelda H Cheung; Eric Chevet; Hui-Ling Chiang; Roberto Chiarelli; Tomoki Chiba; Lih-Shen Chin; Shih-Hwa Chiou; Francis V Chisari; Chi Hin Cho; Dong-Hyung Cho; Augustine M K Choi; DooSeok Choi; Kyeong Sook Choi; Mary E Choi; Salem Chouaib; Divaker Choubey; Vinay Choubey; Charleen T Chu; Tsung-Hsien Chuang; Sheau-Huei Chueh; Taehoon Chun; Yong-Joon Chwae; Mee-Len Chye; Roberto Ciarcia; Maria R Ciriolo; Michael J Clague; Robert S B Clark; Peter G H Clarke; Robert Clarke; Patrice Codogno; Hilary A Coller; María I Colombo; Sergio Comincini; Maria Condello; Fabrizio Condorelli; Mark R Cookson; Graham H Coombs; Isabelle Coppens; Ramon Corbalan; Pascale Cossart; Paola Costelli; Safia Costes; Ana Coto-Montes; Eduardo Couve; Fraser P Coxon; James M Cregg; José L Crespo; Marianne J Cronjé; Ana Maria Cuervo; Joseph J Cullen; Mark J Czaja; Marcello D'Amelio; Arlette Darfeuille-Michaud; Lester M Davids; Faith E Davies; Massimo De Felici; John F de Groot; Cornelis A M de Haan; Luisa De Martino; Angelo De Milito; Vincenzo De Tata; Jayanta Debnath; Alexei Degterev; Benjamin Dehay; Lea M D Delbridge; Francesca Demarchi; Yi Zhen Deng; Jörn Dengjel; Paul Dent; Donna Denton; Vojo Deretic; Shyamal D Desai; Rodney J Devenish; Mario Di Gioacchino; Gilbert Di Paolo; Chiara Di Pietro; Guillermo Díaz-Araya; Inés Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Ivan Dikic; Savithramma P Dinesh-Kumar; Wen-Xing Ding; Clark W Distelhorst; Abhinav Diwan; Mojgan Djavaheri-Mergny; Svetlana Dokudovskaya; Zheng Dong; Frank C Dorsey; Victor Dosenko; James J Dowling; Stephen Doxsey; Marlène Dreux; Mark E Drew; Qiuhong Duan; Michel A Duchosal; Karen Duff; Isabelle Dugail; Madeleine Durbeej; Michael Duszenko; Charles L Edelstein; Aimee L Edinger; Gustavo Egea; Ludwig Eichinger; N Tony Eissa; Suhendan Ekmekcioglu; Wafik S El-Deiry; Zvulun Elazar; Mohamed Elgendy; Lisa M Ellerby; Kai Er Eng; Anna-Mart Engelbrecht; Simone Engelender; Jekaterina Erenpreisa; Ricardo Escalante; Audrey Esclatine; Eeva-Liisa Eskelinen; Lucile Espert; Virginia Espina; Huizhou Fan; Jia Fan; Qi-Wen Fan; Zhen Fan; Shengyun Fang; Yongqi Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Jean-Claude Farré; Mathias Faure; Marcus Fechheimer; Carl G Feng; Jian Feng; Qili Feng; Youji Feng; László Fésüs; Ralph Feuer; Maria E Figueiredo-Pereira; Gian Maria Fimia; Diane C Fingar; Steven Finkbeiner; Toren Finkel; Kim D Finley; Filomena Fiorito; Edward A Fisher; Paul B Fisher; Marc Flajolet; Maria L Florez-McClure; Salvatore Florio; Edward A Fon; Francesco Fornai; Franco Fortunato; Rati Fotedar; Daniel H Fowler; Howard S Fox; Rodrigo Franco; Lisa B Frankel; Marc Fransen; José M Fuentes; Juan Fueyo; Jun Fujii; Kozo Fujisaki; Eriko Fujita; Mitsunori Fukuda; Ruth H Furukawa; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Brigitte Galliot; Vincent Galy; Subramaniam Ganesh; Barry Ganetzky; Ian G Ganley; Fen-Biao Gao; George F Gao; Jinming Gao; Lorena Garcia; Guillermo Garcia-Manero; Mikel Garcia-Marcos; Marjan Garmyn; Andrei L Gartel; Evelina Gatti; Mathias Gautel; Thomas R Gawriluk; Matthew E Gegg; Jiefei Geng; Marc Germain; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Pradipta Ghosh; Anna M Giammarioli; Alexandra N Giatromanolaki; Spencer B Gibson; Robert W Gilkerson; Michael L Ginger; Henry N Ginsberg; Jakub Golab; Michael S Goligorsky; Pierre Golstein; Candelaria Gomez-Manzano; Ebru Goncu; Céline Gongora; Claudio D Gonzalez; Ramon Gonzalez; Cristina González-Estévez; Rosa Ana González-Polo; Elena Gonzalez-Rey; Nikolai V Gorbunov; Sharon Gorski; Sandro Goruppi; Roberta A Gottlieb; Devrim Gozuacik; Giovanna Elvira Granato; Gary D Grant; Kim N Green; Aleš Gregorc; Frédéric Gros; Charles Grose; Thomas W Grunt; Philippe Gual; Jun-Lin Guan; Kun-Liang Guan; Sylvie M Guichard; Anna S Gukovskaya; Ilya Gukovsky; Jan Gunst; Asa B Gustafsson; Andrew J Halayko; Amber N Hale; Sandra K Halonen; Maho Hamasaki; Feng Han; Ting Han; Michael K Hancock; Malene Hansen; Hisashi Harada; Masaru Harada; Stefan E Hardt; J Wade Harper; Adrian L Harris; James Harris; Steven D Harris; Makoto Hashimoto; Jeffrey A Haspel; Shin-ichiro Hayashi; Lori A Hazelhurst; Congcong He; You-Wen He; Marie-Joseé Hébert; Kim A Heidenreich; Miep H Helfrich; Gudmundur V Helgason; Elizabeth P Henske; Brian Herman; Paul K Herman; Claudio Hetz; Sabine Hilfiker; Joseph A Hill; Lynne J Hocking; Paul Hofman; Thomas G Hofmann; Jörg Höhfeld; Tessa L Holyoake; Ming-Huang Hong; David A Hood; Gökhan S Hotamisligil; Ewout J Houwerzijl; Maria Høyer-Hansen; Bingren Hu; Chien-An A Hu; Hong-Ming Hu; Ya Hua; Canhua Huang; Ju Huang; Shengbing Huang; Wei-Pang Huang; Tobias B Huber; Won-Ki Huh; Tai-Ho Hung; Ted R Hupp; Gang Min Hur; James B Hurley; Sabah N A Hussain; Patrick J Hussey; Jung Jin Hwang; Seungmin Hwang; Atsuhiro Ichihara; Shirin Ilkhanizadeh; Ken Inoki; Takeshi Into; Valentina Iovane; Juan L Iovanna; Nancy Y Ip; Yoshitaka Isaka; Hiroyuki Ishida; Ciro Isidoro; Ken-ichi Isobe; Akiko Iwasaki; Marta Izquierdo; Yotaro Izumi; Panu M Jaakkola; Marja Jäättelä; George R Jackson; William T Jackson; Bassam Janji; Marina Jendrach; Ju-Hong Jeon; Eui-Bae Jeung; Hong Jiang; Hongchi Jiang; Jean X Jiang; Ming Jiang; Qing Jiang; Xuejun Jiang; Xuejun Jiang; Alberto Jiménez; Meiyan Jin; Shengkan Jin; Cheol O Joe; Terje Johansen; Daniel E Johnson; Gail V W Johnson; Nicola L Jones; Bertrand Joseph; Suresh K Joseph; Annie M Joubert; Gábor Juhász; Lucienne Juillerat-Jeanneret; Chang Hwa Jung; Yong-Keun Jung; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Motoni Kadowaki; Katarina Kagedal; Yoshiaki Kamada; Vitaliy O Kaminskyy; Harm H Kampinga; Hiromitsu Kanamori; Chanhee Kang; Khong Bee Kang; Kwang Il Kang; Rui Kang; Yoon-A Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Arthi Kanthasamy; Vassiliki Karantza; Gur P Kaushal; Susmita Kaushik; Yoshinori Kawazoe; Po-Yuan Ke; John H Kehrl; Ameeta Kelekar; Claus Kerkhoff; David H Kessel; Hany Khalil; Jan A K W Kiel; Amy A Kiger; Akio Kihara; Deok Ryong Kim; Do-Hyung Kim; Dong-Hou Kim; Eun-Kyoung Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; John K Kim; Peter K Kim; Seong Who Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Jason S King; Timothy J Kinsella; Vladimir Kirkin; Lorrie A Kirshenbaum; Katsuhiko Kitamoto; Kaio Kitazato; Ludger Klein; Walter T Klimecki; Jochen Klucken; Erwin Knecht; Ben C B Ko; Jan C Koch; Hiroshi Koga; Jae-Young Koh; Young Ho Koh; Masato Koike; Masaaki Komatsu; Eiki Kominami; Hee Jeong Kong; Wei-Jia Kong; Viktor I Korolchuk; Yaichiro Kotake; Michael I Koukourakis; Juan B Kouri Flores; Attila L Kovács; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Carole Kretz-Remy; Anna M Krichevsky; Guido Kroemer; Rejko Krüger; Oleg Krut; Nicholas T Ktistakis; Chia-Yi Kuan; Roza Kucharczyk; Ashok Kumar; Raj Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Tino Kurz; Ho Jeong Kwon; Albert R La Spada; Frank Lafont; Trond Lamark; Jacques Landry; Jon D Lane; Pierre Lapaquette; Jocelyn F Laporte; Lajos László; Sergio Lavandero; Josée N Lavoie; Robert Layfield; Pedro A Lazo; Weidong Le; Laurent Le Cam; Daniel J Ledbetter; Alvin J X Lee; Byung-Wan Lee; Gyun Min Lee; Jongdae Lee; Ju-Hyun Lee; Michael Lee; Myung-Shik Lee; Sug Hyung Lee; Christiaan Leeuwenburgh; Patrick Legembre; Renaud Legouis; Michael Lehmann; Huan-Yao Lei; Qun-Ying Lei; David A Leib; José Leiro; John J Lemasters; Antoinette Lemoine; Maciej S Lesniak; Dina Lev; Victor V Levenson; Beth Levine; Efrat Levy; Faqiang Li; Jun-Lin Li; Lian Li; Sheng Li; Weijie Li; Xue-Jun Li; Yan-bo Li; Yi-Ping Li; Chengyu Liang; Qiangrong Liang; Yung-Feng Liao; Pawel P Liberski; Andrew Lieberman; Hyunjung J Lim; Kah-Leong Lim; Kyu Lim; Chiou-Feng Lin; Fu-Cheng Lin; Jian Lin; Jiandie D Lin; Kui Lin; Wan-Wan Lin; Weei-Chin Lin; Yi-Ling Lin; Rafael Linden; Paul Lingor; Jennifer Lippincott-Schwartz; Michael P Lisanti; Paloma B Liton; Bo Liu; Chun-Feng Liu; Kaiyu Liu; Leyuan Liu; Qiong A Liu; Wei Liu; Young-Chau Liu; Yule Liu; Richard A Lockshin; Chun-Nam Lok; Sagar Lonial; Benjamin Loos; Gabriel Lopez-Berestein; Carlos López-Otín; Laura Lossi; Michael T Lotze; Peter Lőw; Binfeng Lu; Bingwei Lu; Bo Lu; Zhen Lu; Frédéric Luciano; Nicholas W Lukacs; Anders H Lund; Melinda A Lynch-Day; Yong Ma; Fernando Macian; Jeff P MacKeigan; Kay F Macleod; Frank Madeo; Luigi Maiuri; Maria Chiara Maiuri; Davide Malagoli; May Christine V Malicdan; Walter Malorni; Na Man; Eva-Maria Mandelkow; Stéphen Manon; Irena Manov; Kai Mao; Xiang Mao; Zixu Mao; Philippe Marambaud; Daniela Marazziti; Yves L Marcel; Katie Marchbank; Piero Marchetti; Stefan J Marciniak; Mateus Marcondes; Mohsen Mardi; Gabriella Marfe; Guillermo Mariño; Maria Markaki; Mark R Marten; Seamus J Martin; Camille Martinand-Mari; Wim Martinet; Marta Martinez-Vicente; Matilde Masini; Paola Matarrese; Saburo Matsuo; Raffaele Matteoni; Andreas Mayer; Nathalie M Mazure; David J McConkey; Melanie J McConnell; Catherine McDermott; Christine McDonald; Gerald M McInerney; Sharon L McKenna; BethAnn McLaughlin; Pamela J McLean; Christopher R McMaster; G Angus McQuibban; Alfred J Meijer; Miriam H Meisler; Alicia Meléndez; Thomas J Melia; Gerry Melino; Maria A Mena; Javier A Menendez; Rubem F S Menna-Barreto; Manoj B Menon; Fiona M Menzies; Carol A Mercer; Adalberto Merighi; Diane E Merry; Stefania Meschini; Christian G Meyer; Thomas F Meyer; Chao-Yu Miao; Jun-Ying Miao; Paul A M Michels; Carine Michiels; Dalibor Mijaljica; Ana Milojkovic; Saverio Minucci; Clelia Miracco; Cindy K Miranti; Ioannis Mitroulis; Keisuke Miyazawa; Noboru Mizushima; Baharia Mograbi; Simin Mohseni; Xavier Molero; Bertrand Mollereau; Faustino Mollinedo; Takashi Momoi; Iryna Monastyrska; Martha M Monick; Mervyn J Monteiro; Michael N Moore; Rodrigo Mora; Kevin Moreau; Paula I Moreira; Yuji Moriyasu; Jorge Moscat; Serge Mostowy; Jeremy C Mottram; Tomasz Motyl; Charbel E-H Moussa; Sylke Müller; Sylviane Muller; Karl Münger; Christian Münz; Leon O Murphy; Maureen E Murphy; Antonio Musarò; Indira Mysorekar; Eiichiro Nagata; Kazuhiro Nagata; Aimable Nahimana; Usha Nair; Toshiyuki Nakagawa; Kiichi Nakahira; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Naweed I Naqvi; Derek P Narendra; Masashi Narita; Miguel Navarro; Steffan T Nawrocki; Taras Y Nazarko; Andriy Nemchenko; Mihai G Netea; Thomas P Neufeld; Paul A Ney; Ioannis P Nezis; Huu Phuc Nguyen; Daotai Nie; Ichizo Nishino; Corey Nislow; Ralph A Nixon; Takeshi Noda; Angelika A Noegel; Anna Nogalska; Satoru Noguchi; Lucia Notterpek; Ivana Novak; Tomoyoshi Nozaki; Nobuyuki Nukina; Thorsten Nürnberger; Beat Nyfeler; Keisuke Obara; Terry D Oberley; Salvatore Oddo; Michinaga Ogawa; Toya Ohashi; Koji Okamoto; Nancy L Oleinick; F Javier Oliver; Laura J Olsen; Stefan Olsson; Onya Opota; Timothy F Osborne; Gary K Ostrander; Kinya Otsu; Jing-hsiung James Ou; Mireille Ouimet; Michael Overholtzer; Bulent Ozpolat; Paolo Paganetti; Ugo Pagnini; Nicolas Pallet; Glen E Palmer; Camilla Palumbo; Tianhong Pan; Theocharis Panaretakis; Udai Bhan Pandey; Zuzana Papackova; Issidora Papassideri; Irmgard Paris; Junsoo Park; Ohkmae K Park; Jan B Parys; Katherine R Parzych; Susann Patschan; Cam Patterson; Sophie Pattingre; John M Pawelek; Jianxin Peng; David H Perlmutter; Ida Perrotta; George Perry; Shazib Pervaiz; Matthias Peter; Godefridus J Peters; Morten Petersen; Goran Petrovski; James M Phang; Mauro Piacentini; Philippe Pierre; Valérie Pierrefite-Carle; Gérard Pierron; Ronit Pinkas-Kramarski; Antonio Piras; Natik Piri; Leonidas C Platanias; Stefanie Pöggeler; Marc Poirot; Angelo Poletti; Christian Poüs; Mercedes Pozuelo-Rubio; Mette Prætorius-Ibba; Anil Prasad; Mark Prescott; Muriel Priault; Nathalie Produit-Zengaffinen; Ann Progulske-Fox; Tassula Proikas-Cezanne; Serge Przedborski; Karin Przyklenk; Rosa Puertollano; Julien Puyal; Shu-Bing Qian; Liang Qin; Zheng-Hong Qin; Susan E Quaggin; Nina Raben; Hannah Rabinowich; Simon W Rabkin; Irfan Rahman; Abdelhaq Rami; Georg Ramm; Glenn Randall; Felix Randow; V Ashutosh Rao; Jeffrey C Rathmell; Brinda Ravikumar; Swapan K Ray; Bruce H Reed; John C Reed; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; John J Reiners; Russel J Reiter; Jun Ren; José L Revuelta; Christopher J Rhodes; Konstantinos Ritis; Elizete Rizzo; Jeffrey Robbins; Michel Roberge; Hernan Roca; Maria C Roccheri; Stephane Rocchi; H Peter Rodemann; Santiago Rodríguez de Córdoba; Bärbel Rohrer; Igor B Roninson; Kirill Rosen; Magdalena M Rost-Roszkowska; Mustapha Rouis; Kasper M A Rouschop; Francesca Rovetta; Brian P Rubin; David C Rubinsztein; Klaus Ruckdeschel; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Nelson Ruiz-Opazo; Rossella Russo; Tor Erik Rusten; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Junichi Sadoshima; Tapas Saha; Tatsuya Saitoh; Hiroshi Sakagami; Yasuyoshi Sakai; Ghasem Hoseini Salekdeh; Paolo Salomoni; Paul M Salvaterra; Guy Salvesen; Rosa Salvioli; Anthony M J Sanchez; José A Sánchez-Alcázar; Ricardo Sánchez-Prieto; Marco Sandri; Uma Sankar; Poonam Sansanwal; Laura Santambrogio; Shweta Saran; Sovan Sarkar; Minnie Sarwal; Chihiro Sasakawa; Ausra Sasnauskiene; Miklós Sass; Ken Sato; Miyuki Sato; Anthony H V Schapira; Michael Scharl; Hermann M Schätzl; Wiep Scheper; Stefano Schiaffino; Claudio Schneider; Marion E Schneider; Regine Schneider-Stock; Patricia V Schoenlein; Daniel F Schorderet; Christoph Schüller; Gary K Schwartz; Luca Scorrano; Linda Sealy; Per O Seglen; Juan Segura-Aguilar; Iban Seiliez; Oleksandr Seleverstov; Christian Sell; Jong Bok Seo; Duska Separovic; Vijayasaradhi Setaluri; Takao Setoguchi; Carmine Settembre; John J Shacka; Mala Shanmugam; Irving M Shapiro; Eitan Shaulian; Reuben J Shaw; James H Shelhamer; Han-Ming Shen; Wei-Chiang Shen; Zu-Hang Sheng; Yang Shi; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Takahiro Shintani; Orian S Shirihai; Gordon C Shore; Andriy A Sibirny; Stan B Sidhu; Beata Sikorska; Elaine C M Silva-Zacarin; Alison Simmons; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Anne Simonsen; David A Sinclair; Rajat Singh; Debasish Sinha; Frank A Sinicrope; Agnieszka Sirko; Parco M Siu; Efthimios Sivridis; Vojtech Skop; Vladimir P Skulachev; Ruth S Slack; Soraya S Smaili; Duncan R Smith; Maria S Soengas; Thierry Soldati; Xueqin Song; Anil K Sood; Tuck Wah Soong; Federica Sotgia; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Srinivasa M Srinivasula; Leonidas Stefanis; Joan S Steffan; Ruediger Stendel; Harald Stenmark; Anastasis Stephanou; Stephan T Stern; Cinthya Sternberg; Björn Stork; Peter Strålfors; Carlos S Subauste; Xinbing Sui; David Sulzer; Jiaren Sun; Shi-Yong Sun; Zhi-Jun Sun; Joseph J Y Sung; Kuninori Suzuki; Toshihiko Suzuki; Michele S Swanson; Charles Swanton; Sean T Sweeney; Lai-King Sy; Gyorgy Szabadkai; Ira Tabas; Heinrich Taegtmeyer; Marco Tafani; Krisztina Takács-Vellai; Yoshitaka Takano; Kaoru Takegawa; Genzou Takemura; Fumihiko Takeshita; Nicholas J Talbot; Kevin S W Tan; Keiji Tanaka; Kozo Tanaka; Daolin Tang; Dingzhong Tang; Isei Tanida; Bakhos A Tannous; Nektarios Tavernarakis; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Lance S Terada; Alexei Terman; Gianluca Tettamanti; Karin Thevissen; Craig B Thompson; Andrew Thorburn; Michael Thumm; FengFeng Tian; Yuan Tian; Glauco Tocchini-Valentini; Aviva M Tolkovsky; Yasuhiko Tomino; Lars Tönges; Sharon A Tooze; Cathy Tournier; John Tower; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Ting-Fen Tsai; Mario P Tschan; Takeshi Tsubata; Allan Tsung; Boris Turk; Lorianne S Turner; Suresh C Tyagi; Yasuo Uchiyama; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Vivek K Unni; Maria I Vaccaro; Enza Maria Valente; Greet Van den Berghe; Ida J van der Klei; Wouter van Doorn; Linda F van Dyk; Marjolein van Egmond; Leo A van Grunsven; Peter Vandenabeele; Wim P Vandenberghe; Ilse Vanhorebeek; Eva C Vaquero; Guillermo Velasco; Tibor Vellai; Jose Miguel Vicencio; Richard D Vierstra; Miquel Vila; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Olga V Voitsekhovskaja; Clarissa von Haefen; Marcela Votruba; Keiji Wada; Richard Wade-Martins; Cheryl L Walker; Craig M Walsh; Jochen Walter; Xiang-Bo Wan; Aimin Wang; Chenguang Wang; Dawei Wang; Fan Wang; Fen Wang; Guanghui Wang; Haichao Wang; Hong-Gang Wang; Horng-Dar Wang; Jin Wang; Ke Wang; Mei Wang; Richard C Wang; Xinglong Wang; Xuejun Wang; Ying-Jan Wang; Yipeng Wang; Zhen Wang; Zhigang Charles Wang; Zhinong Wang; Derick G Wansink; Diane M Ward; Hirotaka Watada; Sarah L Waters; Paul Webster; Lixin Wei; Conrad C Weihl; William A Weiss; Scott M Welford; Long-Ping Wen; Caroline A Whitehouse; J Lindsay Whitton; Alexander J Whitworth; Tom Wileman; John W Wiley; Simon Wilkinson; Dieter Willbold; Roger L Williams; Peter R Williamson; Bradly G Wouters; Chenghan Wu; Dao-Cheng Wu; William K K Wu; Andreas Wyttenbach; Ramnik J Xavier; Zhijun Xi; Pu Xia; Gengfu Xiao; Zhiping Xie; Zhonglin Xie; Da-zhi Xu; Jianzhen Xu; Liang Xu; Xiaolei Xu; Ai Yamamoto; Akitsugu Yamamoto; Shunhei Yamashina; Michiaki Yamashita; Xianghua Yan; Mitsuhiro Yanagida; Dun-Sheng Yang; Elizabeth Yang; Jin-Ming Yang; Shi Yu Yang; Wannian Yang; Wei Yuan Yang; Zhifen Yang; Meng-Chao Yao; Tso-Pang Yao; Behzad Yeganeh; Wei-Lien Yen; Jia-jing Yin; Xiao-Ming Yin; Ook-Joon Yoo; Gyesoon Yoon; Seung-Yong Yoon; Tomohiro Yorimitsu; Yuko Yoshikawa; Tamotsu Yoshimori; Kohki Yoshimoto; Ho Jin You; Richard J Youle; Anas Younes; Li Yu; Long Yu; Seong-Woon Yu; Wai Haung Yu; Zhi-Min Yuan; Zhenyu Yue; Cheol-Heui Yun; Michisuke Yuzaki; Olga Zabirnyk; Elaine Silva-Zacarin; David Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Zahra Zakeri; Herbert J Zeh; Scott O Zeitlin; Hong Zhang; Hui-Ling Zhang; Jianhua Zhang; Jing-Pu Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xu Dong Zhang; Mantong Zhao; Yi-Fang Zhao; Ying Zhao; Zhizhuang J Zhao; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Cong-Zhao Zhou; Changlian Zhu; Wei-Guo Zhu; Xiao-Feng Zhu; Xiongwei Zhu; Yuangang Zhu; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Jürgen Zschocke; Brian Zuckerbraun Journal: Autophagy Date: 2012-04 Impact factor: 16.016